Business
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
DUBLIN, April 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it will present new data related to its schizophrenia disease portfolio at
About this update from Alkermes Plc
[{"type":"text","content":" DUBLIN, April 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it will present new data related to its schizophrenia disease portfolio at the 2019 Congress of the Schizophrenia International Research Society (SIRS) in Orlando, Fla., April 10-14, 2019. The company will host an accompanying webcast and conference call at 8:00 a.m. ET on Friday, April 12 to review detailed results from the recently completed ALKS 3831 (olanzapine/samidorphan) ENLIGHTEN-2 phase 3 study and interim results from the ongoing ENLIGHTEN-2 extension safety study. \n\"The first annual SIRS Congress in the U.S. will bring together leaders from the research community who share Alkermes' commitment to scientific advancement and improving outcomes for patients with schizophrenia,\" said Craig Hopkinson, M.D., Chief Medical Officer, and Senior Vice President of Medicines Development and Medical Affairs at Alkermes. \"Alkermes has been a leader in the development of new medicines to treat schizophrenia for nearly two decades, and we look forward to sharing data from our latest innovations in the field, including new details from the ENLIGHTEN-2 study of our investigational oral atypical antipsychotic drug candidate, ALKS 3831, as well as new safety data related to our long-acting injectable atypical antipsychotic, ARISTADA.\"\nAlkermes presentations at SIRS include:\nALKS 3831 \nOral presentation, \"A Combination of Olanzapine and Samidorphan Mitigates the Weight Gain Observed With Olanzapine Alone: Results From the Phase 3 ENLIGHTEN-2 Schizophrenia Study,\" will be presented during the Pharmaceutical Pipeline session on Thursday, April 11, 2019, 3:30–5:30 p.m. ET. An accompanying poster (#S137) will be available during Poster Session III on Saturday, April 13, 2019, 12:00–2:00 p.m. ET. Poster #T24, \"A Phase 3, Multicenter Study to Assess the Long-Term Safety, Tolerability and Efficacy of a Combination of Olanzapine and Samidorphan in Subjects With Schizophrenia,\" will be available during Poster Session I on Thursday, April 11, 2019, 12:00–2:00 p.m. ET.ARISTADA\nPoster #T23, \"A Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil With a 1-Day Initiation Regimen in Acutely Ill Patients With Schizophrenia: Rationale, Study Design, and Patient Population at Baseline,\" will be available during Poster Session I o...